Skip to main
LUNG
LUNG logo

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 10%
Hold 30%
Sell 10%
Strong Sell 0%

Bulls say

Pulmonx Corp has demonstrated a strong financial trajectory, achieving total revenue of $83.8 million for the full year 2024, marking a 22% increase from 2023, underpinned by robust domestic sales and significant international growth. The company's strategic advancements in technology, such as the Chartis Pulmonary Assessment System, alongside expanded reimbursement coverage, are expected to drive broader adoption of its innovative treatments, enhancing market potential. Additionally, the record worldwide revenue of $23.8 million in Q4 2024, a 23% year-over-year increase, reflects growing confidence among physicians and sustained adoption of Pulmonx's solutions in clinical practice.

Bears say

Pulmonx Corp reported a gross profit of $17.6 million for the quarter, with a slight decline in gross margin to 74%, down from 75% in the previous quarter, indicating potential challenges in maintaining profitability. The company also experienced a decrease in cash reserves, with cash, cash equivalents, and marketable securities falling to $101.5 million from $107.8 million, raising concerns about its liquidity and financial stability. Additionally, as a small capital company, Pulmonx faces inherent volatility and risk, compounded by the growing incidences of COPD in aging populations, which may limit its market expansion capabilities and heighten competitive pressures.

Pulmonx (LUNG) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 10% recommend Buy, 30% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 10 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.